Volume 23, Number 6—June 2017
Research
Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015–2016
Table 3
Year | Surveillance population | % CIS | No. 35B isolates from patients by age, y |
Relative incidence of 35B IPD† | Pen MIC, μg/mL |
penNS 35B isolates/penS 35B isolates | |||
---|---|---|---|---|---|---|---|---|---|
<5 | ≥5 | >2 | 0.12−1 | <0.06 | |||||
1998 | 17,383,935 | 86.1 | 3 | 18 | 1.40 | 9 | 5 | 7 | 2.0 |
1999 | 18,550,681 | 87.0 | 2 | 18 | 1.24 | 8 | 3 | 9 | 1.2 |
2000 | 19,821,607 | 86.3 | 4 | 21 | 1.46 | 7 | 9 | 9 | 1.8 |
2001 | 22,479,308 | 88.1 | 2 | 40 | 2.12 | 14 | 18 | 10 | 3.2 |
2002 | 25,051,246 | 87.6 | 2 | 34 | 1.64 | 20 | 8 | 8 | 3.5 |
2003 | 25,264,246 | 91.4 | 11 | 49 | 2.56 | 22 | 26 | 11 | 4.4 |
2004 | 27,419,898 | 87.9 | 15 | 69 | 3.49 | 44 | 25 | 15 | 4.6 |
2005 | 27,816,784 | 89.5 | 11 | 57 | 2.73 | 35 | 18 | 15 | 3.5 |
2006 | 28,204,455 | 86.7 | 1 | 65 | 2.70 | 37 | 15 | 14 | 3.7 |
2007 | 28,579,312 | 87.5 | 5 | 83 | 3.52 | 51 | 23 | 14 | 5.3 |
2008 | 28,856,774 | 86.7 | 12 | 80 | 3.68 | 62 | 16 | 14 | 5.6 |
2009 | 29,206,528 | 89.8 | 8 | 70 | 2.97 | 45 | 16 | 17 | 3.6 |
2010 | 29,757,552 | 90.2 | 4 | 67 | 2.65 | 52 | 14 | 5 | 13.2 |
2011 | 30,075,050 | 90.3 | 11 | 77 | 3.28 | 71 | 7 | 10 | 7.8 |
2012 | 30,356,544 | 90.6 | 13 | 101 | 4.14 | 94 | 14 | 6 | 18.0 |
2013 | 30,604,240 | 88.7 | 15 | 114 | 4.75 | 94 | 25 | 10 | 11.9 |
2014 | 31,328,211 | 88.2 | 16 | 116 | 4.78 | 104 | 22 | 6 | 21.0 |
2015 | 31,977,800 | 92.0 | 10 | 121 | 4.45 | 101 | 24 | 6 | 20.8 |
*CIS, case isolates serotyped; IPD, invasive pneumococcal disease.
†Estimated cases/million = total 35Bs x 100/% CIS surveillance population/1,000,000.
Page created: May 16, 2017
Page updated: May 16, 2017
Page reviewed: May 16, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.